Opus Genetics, Inc. Common Stock (IRD) Stock
Fundamentals
Recent news

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
IRD

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
IRD

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
IRD

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
IRD
Technicals
Analyst Ratings
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
% positive news of 5 articles
published over the past 14 days
Latest news

IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
IRD

Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
IRD

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst
IRD

Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q1 Loss, Misses Revenue Estimates
IRD

Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
Opus Genetics, Inc. (IRD) Reports Q4 Loss, Tops Revenue Estimates
IRD
About Opus Genetics, Inc. Common Stock
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA), and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. George Magrath M.B.A., M.D., M.S. | CEO & Director | 1985 |
| Dr. Benjamin R. Yerxa Ph.D. | President & Director | 1966 |
| Mr. Joseph K. Schachle MBA | Chief Operating Officer | 1965 |
| Dr. Ashwath Jayagopal M.B.A., Ph.D. | Chief Scientific & Development Officer | 1983 |
| Mr. Chris Ernst | Chief Technology Officer | — |
| Ms. Jenny Kobin | Investor Relations Officer | — |
| Mr. Bernhard Hoffmann M.B.A. | Senior Vice President of Corporate Development & Secretary | 1956 |
| Ms. Amy Zaremba Rabourn C.P.A., MAcc | Head of Financial Quality Assurance | 1981 |
| Ms. Bindu Manne | Head of Market Development & Commercialization | — |
| Ms. Sally Tucker Ph.D. | Chief Medical Officer & Senior Vice President of Clinical Development | — |
Fundamentals
Valuation
Earnings Per Share
Income Statement
Dividend
Solvency
Technicals
What the experts say
6 Wall Street Analyst Ratings
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.6 | +79.3 | +5.1 | +9.0 | -15.2 | -0.2 | -11.2 | -0.5 | +24.3 |



